1
|
Niloy KK, Lowe TL. Injectable systems for long-lasting insulin therapy. Adv Drug Deliv Rev 2023; 203:115121. [PMID: 37898336 DOI: 10.1016/j.addr.2023.115121] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Revised: 10/20/2023] [Accepted: 10/25/2023] [Indexed: 10/30/2023]
Abstract
Insulin therapy is the mainstay to treat diabetes characterizedd by hyperglycemia. However, its short half-life of only 4-6 min limits its effectiveness in treating chronic diabetes. Advances in recombinant DNA technology and protein engineering have led to several insulin analogue products that have up to 42 h of glycemic control. However, these insulin analogues still require once- or twice-daily injections for optimal glycemic control and have poor patient compliance and adherence issues. To achieve insulin release for more than one day, different injectable delivery systems including microspheres, in situ forming depots, nanoparticles and composite systems have been developed. Several of these delivery systems have advanced to clinical trials for once-weekly insulin injection. This review comprehensively summarizes the developments of injectable insulin analogs and delivery systems covering the whole field of injectable long-lasting insulin technologies from prototype design, preclinical studies, clinical trials to marketed products for the treatment of diabetes.
Collapse
Affiliation(s)
- Kumar Kulldeep Niloy
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
| | - Tao L Lowe
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Maryland, Baltimore, MD 21201, USA; Fischell Department of Bioengineering, A. James Clark School of Engineering, University of Maryland, College Park, MD 20742, USA.
| |
Collapse
|
3
|
Zhai P, Chen XB, Schreyer DJ. PLGA/alginate composite microspheres for hydrophilic protein delivery. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2015; 56:251-9. [PMID: 26249587 DOI: 10.1016/j.msec.2015.06.015] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Revised: 05/11/2015] [Accepted: 06/09/2015] [Indexed: 11/16/2022]
Abstract
Poly(lactic-co-glycolic acid) (PLGA) microspheres and PLGA/alginate composite microspheres were prepared by a novel double emulsion and solvent evaporation technique and loaded with bovine serum albumin (BSA) or rabbit anti-laminin antibody protein. The addition of alginate and the use of a surfactant during microsphere preparation increased the encapsulation efficiency and reduced the initial burst release of hydrophilic BSA. Confocal laser scanning microcopy (CLSM) of BSA-loaded PLGA/alginate composite microspheres showed that PLGA, alginate, and BSA were distributed throughout the depths of microspheres; no core/shell structure was observed. Scanning electron microscopy revealed that PLGA microspheres erode and degrade more quickly than PLGA/alginate composite microspheres. When loaded with anti-laminin antibody, the function of released antibody was well preserved in both PLGA and PLGA/alginate composite microspheres. The biocompatibility of PLGA and PLGA/alginate microspheres were examined using four types of cultured cell lines, representing different tissue types. Cell survival was variably affected by the inclusion of alginate in composite microspheres, possibly due to the sensitivity of different cell types to excess calcium that may be released from the calcium cross-linked alginate.
Collapse
Affiliation(s)
- Peng Zhai
- Department of Anatomy and Cell Biology, University of Saskatchewan, S7N5E5, Canada; Division of Biomedical Engineering, University of Saskatchewan, S7N5A9, Canada
| | - X B Chen
- Department of Mechanical Engineering, University of Saskatchewan, S7N5A9, Canada; Division of Biomedical Engineering, University of Saskatchewan, S7N5A9, Canada
| | - David J Schreyer
- Department of Anatomy and Cell Biology, University of Saskatchewan, S7N5E5, Canada; Division of Biomedical Engineering, University of Saskatchewan, S7N5A9, Canada.
| |
Collapse
|
4
|
Han Y, Zeng Q, E L, Wang D, He H, Liu H. Sustained Topical Delivery of Insulin From Fibrin Gel Loaded With Poly(Lactic-Co-Glycolic Acid) Microspheres Improves the Biomechanical Retention of Titanium Implants in Type 1 Diabetic Rats. J Oral Maxillofac Surg 2012; 70:2299-308. [DOI: 10.1016/j.joms.2012.05.028] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Revised: 05/09/2012] [Accepted: 05/27/2012] [Indexed: 11/24/2022]
|
5
|
Presmanes C, de Miguel L, Espada R, Alvarez C, Morales E, Torrado JJ. Effect of PLGA hydrophilia on the drug release and the hypoglucemic activity of different insulin-loaded PLGA microspheres. J Microencapsul 2011; 28:791-8. [PMID: 21967461 DOI: 10.3109/02652048.2011.621554] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The effects of viscosity and hydrophilic characteristics of different PLGA polymers on the microencapsulation of insulin have been studied in vitro and in vivo after subcutaneous administration to hyperglycemic rats. Hydrophilic PLGA polymers produced a higher burst effect than the hydrophobic ones. Moreover, an incomplete insulin release was observed with the hydrophilic PLGA polymers in comparison with the hydrophobic ones. An explanation for that incomplete release can be the development of polymer-insulin interactions associated to the polymer hydrophilic/hydrophobic character, as detected by DSC analysis. Differences in the release rate of microsphere formulations lead to differences in the hypoglycemic action and the weight of animals. Hydrophobic PLGA was able to prolong the hypoglycemic action up to 4 weeks which is at least double than that obtained with hydrophilic PLGA of a similar viscosity. Comparing insulin microspheres with an immediate release formulation, microspheres can increase insulin relative bioavailability up to four times.
Collapse
Affiliation(s)
- C Presmanes
- Instituto de Farmacia Industrial, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal sn 28040, Spain
| | | | | | | | | | | |
Collapse
|
6
|
Kim BS, Oh JM, Hyun H, Kim KS, Lee SH, Kim YH, Park K, Lee HB, Kim MS. Insulin-Loaded Microcapsules for In Vivo Delivery. Mol Pharm 2009; 6:353-65. [DOI: 10.1021/mp800087t] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Byung Soo Kim
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Jae Min Oh
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Hoon Hyun
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Kyung Sook Kim
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Sang Hyo Lee
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Yu Han Kim
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Kinam Park
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Hai Bang Lee
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| | - Moon Suk Kim
- Fusion Biotechnology Research Center, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong, Daejeon 305-600, Korea, and Departments of Biomedical Engineering and Pharmaceutics, Purdue University, 206 S. Intramural Drive, West Lafayette, Indiana 47907-1791
| |
Collapse
|